Avacincaptad Pegol for Geographic Atrophy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).
Research Team
Medical Director
Principal Investigator
Astellas Pharma Global Development, Inc.
Eligibility Criteria
This trial is for patients aged 50 or older with a condition called Geographic Atrophy, who completed the GATHER2 study. They must be able to attend all visits over an 18-month period and not have dropped out of the previous study due to side effects.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive avacincaptad pegol 2 mg monthly from Month 1 to Month 17
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue to receive avacincaptad pegol to assess long-term safety
Treatment Details
Interventions
- Avacincaptad Pegol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Astellas Pharma Global Development, Inc.
Lead Sponsor
Tadaaki Taniguchi
Astellas Pharma Global Development, Inc.
Chief Medical Officer
M.D., Ph.D.
Naoki Okamura
Astellas Pharma Global Development, Inc.
Chief Executive Officer
Not available
IVERIC bio, Inc.
Lead Sponsor